loading...

Myasthenia Gravis Activities of Daily Living Profile (MG-ADL)

Wolfe GI; Herbelin L; Nations SP; Bryan WW; Barohn RJ; Foster B

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Published in 1999

Authors

Wolfe GI; Herbelin L; Nations SP; Bryan WW; Barohn RJ; Foster B

Copyright
© 1997 UT Southwestern Medical Center, Dallas
Objective
To assess the severity of Myasthenia Gravis (MG) symptoms
Therapeutic area
  • Neoplasms
  • Nervous System Diseases
  • Immune System Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Myasthenia Gravis For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999 Apr 22;52(7):1487-9 (PubMed abstract)

Muppidi S, Wolfe GI, Conaway M, Burns TM; MG COMPOSITE AND MG-QOL15 STUDY GROUP. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011 Nov;44(5):727-31 (Pubmed Abstract)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

Wolfe GI; Herbelin L; Nations SP; Bryan WW; Barohn RJ; Foster B

Gil I. Wolfe, MD, FAAN
Irvin and Rosemary Smith Professor and Chair
Dept. of Neurology/Jacobs Neurological Institute
Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences/SUNY
Buffalo General Medical Center
100 High St.
Buffalo, NY 14203-1126
Phone: 716-859-2024
Fax: 716-859-2430
E-mail: gilwolfe@buffalo.edu

Laura Herbelin
E-mail: LHERBELIN@kumc.edu

Richard Barohn
E-mail: RBAROHN@kumc.edu

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

MG-ADL

Chinese for Hong Kong*
Czech for Czech Republic*
Danish for Denmark*
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Canada*
English for the UK*
French for Belgium*
French for Canada*
French for France*
Georgian for Georgia*
German for Belgium*
German for Germany*
Hungarian for Hungary*
Italian for Italy*
Japanese for Japan*
Korean for South Korea*
Mandarin for Taiwan*
Polish for Poland*
Portuguese for Portugal*
Russian for Russia*
Serbian for Serbia*
Spanish for Spain*
Spanish for the USA*
Swedish for Sweden*
Turkish for Turkey*
* Performed by Mapi/ICON

Conditions to translate

Recommended vendor for translation work: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

E-versions

Conditions of Use

A license agreement must be completed and a user fee is required by all users (commercial & academic users) and a screenshot review agreement must be signed by commercial users. Please submit a request.

Conditions to Implement in Electronic Applications

The work performed can be certified once it has been confirmed as being in line with the instructions of the MG-ADL e-Booklet.

Screenshots review of the original version:

 The review of the screenshots is mandatory and should be performed exclusively by MRT. This work is subject to a specific budget
 The review of the screenshots is not mandatory but can be performed by MRT. This work is subject to a specific budget
 The review of the screenshots is mandatory and should be performed exclusively by the Authors

Usability testing of the original version performed by Experts:

If applicable for a specific scope and budget, after implementation of the MG-ADL into the device(s), the User and/or eCOA Company will provide Mapi/ICON with a test device or the on-line connection, in order to assess the overall usability of the solution, with the target patient population(s) in mind including clarity, navigation, font size, and device usability.

Screenshots review of target language:

The review of target language screenshots is mandatory and should be performed exclusively by Mapi/ICON. This work is subject to a specific budget
The review of target language screenshots is not mandatory but can be performed by Mapi/ICON. This work is subject to a specific budget
The review of target language screenshots is mandatory and should be performed exclusively by the Authors

e-Booklets Information

The Questionnaire e-Booklet, developed in collaboration with the Owner, is intended to accompany the User through the development of official, validated, and approved electronic versions of the Questionnaire. It includes instructions and checklists on instrument properties and configuration, content, navigation, workflow diagram, format and provides a model about how the electronic version of the Questionnaire must be displayed (i.e. the “Original electronic Versions” (“OeVs”) of the Questionnaire).

e-Booklet Status:

Yes
Under Development
No

e-Booklet Current Version: MG-ADL_AU1.1_eng-US_e-Booklet_1.0

Compatible Devices:

Handheld Device  
Tablet
Web(1)(2)(3)  
BYOD(3)

Please do make sure to consider the target population when selecting a device for a specific study.

(1)for password protected clinical trial projects only.
(2)Web versions should only be authorized for screens of 1024px or larger, i.e. mobile device cannot access the Web versions or a disclaimer should be stated otherwise. Upon termination of the User Agreement between the User and MRT, the User shall immediately cease the use of the e-PRO and shall destroy any material related to the e-PRO in the system by erasing them from the magnetic mediate on which they are stored and certify in writing that they have been destroyed.
(3)The User acknowledges that devices, non-compliant with the approved modalities specification as detailed above, will not be certified. The User shall be responsible for any consequences arising out from the use by the patients of any non-approved devices and in particular non-approved screen sizes.

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us